Richard Rodgers

ADC is a global leader in providing network infrastructure products and services that enable the profitable delivery of high-speed Internet, video, data, and voice services to residential, business and mobile subscribers worldwide. Their innovative, high-performance fiber connectivity and wireless coverage and capacity solutions support a broad range of network applications that help their customers provide new and advanced services to meet their own customers' unrelenting demand for bandwidth. Founded 75 years ago, ADC continues to build on a strong heritage of providing solutions and services that support its customers' migration to next-generation networks in many countries across the globe. As the leading service providers and enterprises worldwide invest in infrastructure that delivers broadband services to business, residential and mobile subscribers, ADC's breadth of solutions and experience, together with its strong financial position, make the company a reliable partner in addressing today's network realities and preparing for tomorrow's communications demands.

MGI PHARMA, INC. develops, manufactures & markets pharmaceutical and medical products for therapeutic markets. The company's products include Aloxi injection, Dacogen, Gliadel water, Hexalen capsules, and Salagen Tablets. It has alliances with Helsinn Healthcare SA, Kissei Pharmaceutical Co. Ltd., Dainippon Pharmaceutical Co. Ltd., Pfizer, Inc. and Novartis Pharma AG. The company was founded in 1979 and is headquartered in Bloomington, MN.

MedSource Technologies Holdings LLC provides engineering, manufacturing, and supply chain management services for the medical device industry. The company was founded by Andrew D. Lipman, Richard J. Effress, and William John Kidd on April 1998 and is headquartered in Wilmington, MA.

Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA.

TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. The firm offers Niraparib products. The company was founded by Leon Oliver Moulder, Jr., Mary Lynne Hedley, and Richard J. Rodgers on March 26, 2010 and is headquartered in Waltham, MA.